Navigation Links
Advanced Health Care Options for People With Diabetes
Date:10/28/2008

MINNEAPOLIS, Oct. 28 /PRNewswire/ -- It's estimated that almost 2.5 million Latinos in the U.S. will be affected by diabetes by 2020, of those, 44% will be over the age of 65. So even just within the Hispanic community, the effects of diabetes are vividly present. While Medicare can cover medical services, the coordination and monitoring of those services is particularly critical to managing complicated medical conditions.

It's widely known that diabetes is a debilitating disease requiring careful and consistent medical attention. What may not be as clear, however, are the solutions to manage the multiple needs of the disease that can range from juggling multiple physicians and treatment plans to coping with the demands of a hectic pace in a fast-food society.

"Diabetes is the seventh leading cause of death listed on U.S. death certificates," said Dr. Ana Fuentevilla, Evercare Medical Director. Furthermore, diabetes is the leading cause of kidney failure and new cases of blindness, as well as a strong influencer in the cases of high blood pressure, dental disease, heart disease, strokes and amputations (1).

To ensure the proper management of diabetes, it's important to follow the specific treatments prescribed by the primary health care provider and specialists because failure to adhere to them could severely jeopardize one's health. To facilitate the management of what may turn into a multitude of treatments, doctor's appointments and medications often requires special health care and insurance plans developed for people with chronic illnesses in mind. Evercare(R), http://www.planesdesaludevercare.com, a leading provider of Medicare Advantage Special Needs Plans, offers health plans tailored to meet the needs of people living with one or more chronic illnesses who are also eligible for Medicare.

There are several programs tailored to special needs cases, such as for
'/>"/>

SOURCE Evercare
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Doctors Test Advanced Tool for Treating Prostate Cancer
2. Relations PR & Marketing Named Agency of Record for Advanced Ultrasound Services
3. Glycotex Finalizes Collaboration Agreement with Advanced Medical Solutions
4. Advanced Circulatory Systems Receives $1.5 Million From NIH for Study of Cardiac Arrest Resuscitation Techniques
5. Advanced Life Sciences and Wyeth Sign Commercialization Agreement for Cethromycin in Asia Pacific Region
6. 27 National Nursing Organizations Join Together to Commission a Study of the Impact of Advanced Practice Registered Nurses on Healthcare Quality, Safety, and Effectiveness
7. Varian Medical Systems Signs Collaboration Agreement to Bring Advanced Radiotherapy Equipment to Indonesia
8. Advanced blood analysis may speed diagnosis of heart attacks
9. AdvancedMD Named to Inc. 5000 List of America's Fastest-Growing Companies : Web-based Software Leader Ranked No. 44 in the Top 100 Software Companies
10. Medical Spa Consulting from Best Medspa in America to Provide Advanced Medical Spa Education at Medspa Conference in Orlando, FL
11. Sweden to Receive Scandinavia's First TomoTherapy System : Lund University Hospital to Offer Swedish Cancer Patients the Most Advanced Image-Guided Radiation Therapy Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 On October 22, ... featuring skin diseases both fictional and real. The ... a nonprofit organization committed to advocacy and philanthropy in ... will take the opportunity to impart truth and clarity ... , There are many misconceptions about Morgellons Disease ...
(Date:10/22/2014)... Arbor, MI (PRWEB) October 22, 2014 ... of Schools of Allied Health Professions (ASAHP) Conference on ... Founder and CEO will participate in a panel discussion ... and Practice. , Isabel Healthcare provides a diagnostic decision ... in improving the diagnosis skills of students and clinical ...
(Date:10/22/2014)... Amy Norton HealthDay Reporter ... remain riveted on the three Ebola cases in Dallas. But, ... health threat to Americans. President Barack Obama on Friday ... the virus, which has infected two Dallas nurses who cared ... at Texas Health Presbyterian Hospital. But the U.S. cases ...
(Date:10/22/2014)... 22, 2014 Shriners Hospitals for Children® ... change the current location of Shriners Hospitals for Children ... across from the University of Kentucky Albert B. Chandler ... care center, owned and operated by Shriners Hospitals for ... of children and their families well into the future. ...
(Date:10/22/2014)... Los Angeles, California (PRWEB) October 22, 2014 ... Recovery 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; ... the field of Yoga & Recovery. This book is ... and thrive in a life of recovery. , Recovery ... of the 12 Steps; Recovery 2.0 is a guide for ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3
... , FRIDAY, Nov. 11 (HealthDay News) -- Certain types ... smokers who are generally anxious, according to a new study. ... to tune out anti-smoking videos that warn how smoking can ... harm others. "If you look at health messages, there ...
... Experts from The Neuroscience Institute at NYU Langone Medical ... discussions at the Society for Neuroscience 41st Annual Meeting ... meeting presents an opportunity for leading scientists from around ... for treating diseases and conditions of the brain," said ...
... Researchers at the University of Liverpool and the universities ... that cases of severe pneumonia among young children are ... cooking stoves. The research, published in the ... smoke from open fires and dirty cooking stoves, the ...
... scientists have developed a new technique using stem cells, ... disease. The technique could be developed for application in ... Thompson lead the research from the Florey Neuroscience Institutes ... the newly established Stem Cells Australia collaboration being launched ...
... THURSDAY, Nov. 10 (HealthDay News) -- Despite the known dangers ... but almost 70 percent want to quit, a new government ... Tim McAfee, director of the Office on Smoking and Health ... during a noon press conference Thursday. There was a ...
... (HealthDay News) -- Eating a high-fiber diet may reduce your ... cereal and whole grains, according to a new review. ... a total of nearly 2 million people. Compared with the ... increase in intake of total dietary fiber and cereal fiber ...
Cached Medicine News:Health News:Negative Anti-Smoking Ads Turn Off Anxious Viewers 2Health News:Woodsmoke from cooking fires linked to pneumonia 2Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 2Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 3Health News:Most Smokers Want to Quit, CDC Report Finds 2Health News:Most Smokers Want to Quit, CDC Report Finds 3Health News:Most Smokers Want to Quit, CDC Report Finds 4Health News:High-Fiber Diet May Help Thwart Colon Cancer 2
(Date:10/22/2014)... Oct. 22, 2014 WHEN: Wednesday, October 29, ... registration available at: http://bit.ly/1yStiU9 SPEAKERS: ... and Visionary Innovation Research Group Senior Research ... self-assembling materials, nanobots and flexible electronics are ... transform our lives in the coming decades. ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)...  Luoxis Diagnostics, Inc., a subsidiary of Ampio ... its academic collaborators will present several peer-reviewed posters ... novel RedoxSYS Diagnostic System, a first-in-class platform that ... response to injury or illness.  A poster demonstrating ... marker will be presented by Christopher V. ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... A of Trial Assessing Regimen of ... TUSTIN, Calif., Oct. 7 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... for the treatment of cancer and,hepatitis C virus (HCV) ... first stage of a Phase II trial of bavituximab ...
... TOKYO and CHIPPENHAM, England, October 7 ,Sosei ... and Vectura,Group plc ("Vectura"; LSE: VEC), announce ... efficacy, safety and tolerability of NVA237 presented ... Society (ERS) in Berlin,Germany. The new data ...
Cached Medicine Technology:Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5
... Peel PRESTIGE system was designed with advanced ... of the most demanding skin care practice. ... the Parisian Peel PRESTIGE machine is designed ... to offer maximum versatility and full abrasion ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
Latex agglutination inhibition slide test for the qualitative detection of hCG in urine....
Test for the quantitative determination of antideoxyribonuclease-B (ADNase-B) in serum....
Medicine Products: